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 الاهذاء
ارمذَ ثأسّٝ آ٠بد اٌشىش ٚالاِزٕبْ ٚاٌزمذ٠ش ٚاٌّحجخ إٌٝ اٌز٠ٓ حٍّٛا ألذط سسبٌخ فٟ 
 اٌح١بح...
 ٚ ِٙذٚا ٌٕب ؽش٠ك اٌؼٍُ ٚاٌّؼشفخ...
 إٌٝ خّ١غ أسبرزرٟ الأفبػً.
ٚاخض ثبٌشىش ٚاٌزمذ٠ش اٌجشٚفسٛس سف١ك لشِبْ, غٍٝ خٙٛدٖ ٚػٍٝ ِب افبػٗ ػٍٟ ِٓ
ث١ٗ.ِؼشفخ خلاي سحٍزٟ اٌجح
 ٚلا ثذ ٌٟ ِٓ ٚلفخ اخلاي ٚحت ٚرمذ٠ش.....
اٌٝ ِٓ احًّ اسّٗ ثىً فخش, ٚ٠شرؼش لٍجٟ ٌزوشٖ. اٌٝ ِٓ خشع اٌىبط فبسغب ٌ١سم١ٕب 
 لطشح حت....
ٚاٌٝ ِٓ اسػؼزٕٟ اٌحت ٚاٌحٕبْ, سِض إٌمبء ٚاٌظفبء ٚثٍسُ اٌشفبء, اٌٝ اػظُ ٚأمٝ 
 أسبٔٗ....
  ا ٌٕب ؽش٠ك اٌؼٍُ....٠ب ِٓ حظذا الاشٛان ػٓ دسٚثٕب ٌ١ّٙذ
 اثٟ اٌؼض٠ض (ٚػبذ), ٚاِٟ اٌغبٌ١ٗ ( خّ١ٍٗ).
 اٌٝ صٚخٟ اٌغبٌٟ ٚسف١ك دسثٟ سف١بْ.
  ًِ.اٌٝ لشح ػ١ٕٟ ٚفٍزح وجذٞ اثٕزٟ وش
 اٌٝ اٌمٍٛة اٌطب٘شٖ اٌشل١مٗ ٚس٠بح١ٓ اٌح١بٖ...
 اخٟ ِحّذ ٚاخٛارٟ اٌحبْ, دأ١ٗ, ا٠ّبْ ٚ ٘جٗ.
  سث١ؼٙب اثٕبء شم١مبرٟ ٚشم١مٟ , شىشٞ, سٍ١ّبْ ٍِٚه.اٌٝ إٌفٛط اٌجش٠ئٗ ٚ ثسّخ اٌح١بٖ ٚ
مجٍٗ ِٕٟ ٚاْ ٠دذ اٌمجٛي ا٘ذ٠ىُ خّ١ؼب ٘زا اٌجحث,  ساخ١خ ِٓ اٌٌّٛٝ ػض ٚخً اْ ٠ز
دبذٚإٌ
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ABSTRACT: 
Malaria is a global public health problem, resulting in tow million deaths per year .The 
majority of death cases are due to the most severe form of malaria caused by Plasmodium 
falciparum. As a result, efforts were directed toward the development of new effective 
medications intended for the treatment of this endemic disease. Atovaqoune is a new 
treatment option, showed an improvement in malaria treatment. Although Atovaqoune is 
an effective medication, it has its own limitations. 
Atovaqoune is highly lipophilic compound (water solubility < 0.2 µg/ mL), has low water 
solubility and low absorption, hence low bioavailability (< 10% in the fasted state). 
Accordingly, increasing atovaqoune aqueous solubility will improve its pharmacokinetic 
profile in particular bioavailability, thus improving its effectiveness and ability to 
administer the drug through different routs of administration. 
So that, our goal was to develop atovaqoune prod rug that possesses increased aqueous 
solubility by linking water soluble moiety to the 3- hydroxyl group, via chemical synthesis. 
Purification techniques including extraction, re-crystallization and column chromatography 
were used. Identity confirmation was done using, IR, NMR and LC/MS. Based on purity 
and identity results; in vitro kinetic studies using the HPLC instrument were performed at 
pH 2.2, 5.5 and 7.4.   
ATQ succinate (ProD1) has been successfully synthesized, purified and evaluated. T1/2 of 
ProD1 at pH 2.2, 5.5 and 7.4 is 28.8 days, 2.2 days, 3.2 days, respectively. 
It can be concluded from these data, that ProD1 is converted into ATQ in pH dependent 
manner, and the hydrolysis of the prodrug follows first order kinetics, as the data plotted 
gives a straight line,  and the Kobs is nearly constant. Concisely, modifying atovaqoune 
structure may result in enhancing its pharmacokinetic profile mainly absorption into body 
tissues, consequently increasing efficacy and ability to formulate atovaqoune in different 
dosage forms. 
Keywords: Malaria, drug resistance, atovaquone, bioavailability, prodrugs. 
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Chapter One 
Introduction 
 
1.1 Background 
1.1.1 Malaria 
 
Malaria is a global public health problem, affecting 40% of the population (300 million 
clinical cases annually) and causes~ 2 million deaths per year [1, 2]. 
 
Most of disease cases are found in tropical Africa, Latin America, Southern Asia and 
Oceania  [3]. World Health Organization (WHO) assesses that 81% of cases and 91% of 
deaths are found to be in WHO African regions. Children under 5years old and pregnant 
women are the most severely affected. This protozoan disease is caused by 5 parasites 
species of the genus Plasmodium that affect humans (P. falciparum, P. vivax, P. ovale, P. 
malariae and P. knowlesi) [4]. Most of death cases are caused by the most severe form P. 
falciparum, which dominate in Africa and to which most drug-resistant cases are 
attributed. Malaria is transmitted to humans via the bite of infected female mosquito of 
anopheles species. Malaria can exist, in a mild form that most commonly associated with 
flu-like symptoms; fever, vomiting, and general malaise. While in the sever form caused 
by P. falciparum, a nervous, respiratory and renal complications frequently coexist due to 
serious organ failure [5]. Despite of being serious infectious disease, Malaria is a treatable 
and preventable illness and a number of treatments are already available [4]. 
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1.1.1.1 Malaria treatment medications 
 
A brief description of the major therapeutic groups of malaria including chloroquine, 
antifolates, artemisinins and atovaquone are provided below. 
1.1.1.1.1 Chloroquine 
 
Chloroquine a 4-aminoquinoline, act by accumulating inside the digestive vacuole of the 
infected red blood cell, where it makes complexes with toxic heme moieties and disturbs 
the detoxification mechanisms that involve heme sequestration into an inert pigment called 
hemozoin[6]. It is an inexpensive drug used to prevent and treat malaria for decades. 
However, the emergence of chloroquine resistance in the vast majority of malaria-endemic 
countries, and the association of tinnitus and central nervous system toxicity with 
chloroquine treatment limit its use [7] [8].  
 
1.1.1.1.2 Antifolates 
 
Currently used antifolate combinations of sulfadoxine- pyrimethamine and sulfalene-
pyrimethamine have long elimination half-lives, 81 hours for sulfadoxine, 62 hours for 
sulfalene and 116 hours for pyrimethamine [9], [10]. This has both advantages and 
disadvantages. On the one hand, it allows single-dose therapy and persistence of the drugs 
at effective blood levels might protect the patients from reinfections after cure of the initial 
disease. On the other hand, the latter would be only useful in high transmission areas and 
the slow elimination favors the selection of resistant parasites[11]. There is also concern 
with adverse reactions to long-acting sulfonamides [12], especially in subjects 
concomitantly infected with human immunodeficiency virus (HIV) infections [13].  
As indicated from the name ‘antifolates’, they antagonize the action of folic acid by 
inhibiting dihydrfolate reductase (DHFR) enzyme, hence inhibiting cell division. [14] 
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1.1.1.1.3 Artemisinin 
 
Replacing unsuccessful medications (chloroquine), with well tolerated artesunate 
monotherapy and artemisnin combinations resulted in decrease in malaria mortality and 
morbidity [15]
 
.  Artemisinin are commonly used in Southeast Asia [16]. 
The mechanism of action of these compounds appears to involve the heme-mediated 
decomposition of the endoperoxide bridge to produce carbon-centered free radicals [17].
.
In 
spite of their effectiveness, artemisinin resistance appears in several areas mainly in Pailin 
and western Cambodia. Moreover, it is associated with reduced cure rates [18].
   
 
It is worth noting that antimalarial drug resistance escalates to the major therapeutic groups 
used in malaria treatment, which constitutes a major threat to the global malaria control 
[19].
 
This can be attributed to the fact that malaria control has significantly dependent on a 
limited number of chemically related drugs, such as the quinolone or the antifolate groups, 
which are overused in poor countries due to their low price[16]. 
Practice has shown that resistance ultimately shortens the life span of antimalarial drugs. 
Accordingly, this emphasizes the urgent need to develop alternative medications with a 
novel chemical structure and mechanisms of action to treat and prevent malaria in one 
hand, and on the other hand to develop strategies to avoid resistance when new drugs are 
introduced [16]. 
In view of that, efforts were directed toward developing, novel compounds with novel 
mechanisms of action to maintain an effective malaria control.   
 
1.1.1.1.4 Atovaquone 
 
Atovaquone (ATQ) is a hydroxynaphthoquinone figure (1.1). Naphthoquinones are known 
to have antimalarial, anticoccidial and antitheilerial activity [20]. ATQ  is relatively a new 
treatment option, that has a broad antiprotozoan activity including  Plasmodium spp [21], it 
has a novel mechanism of action, acts by inhibition of the electron transport system at the 
level of cytochrome bc1 complex [22] figure(1.2). In malaria parasites, the mitochondria 
act as a sink for the electrons generated from dihydrorotate dehydrogenase; an essential 
enzyme for pyrimidine biosynthesis; Inhibition of electron transport by ATQ leads to 
dihydrorotate dehydrogenase inhibition resulting in reduced pyrimidine biosynthesis and 
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concomitantly, parasite replication  [23]. This is because parasites depend on de novo 
production of pyrimidines and have no salvage pathway; in contrast to humans, thus the 
final outcome is the prevention of parasite replication [24]. It is mentioned in the literature; 
that protozoan electron transport inhibition was about 1000-fold more sensitive than were 
mammalian and avian mitochondria [25]. 
 
 
Figure 1.1: Atovaquone chemical structure. 
 
 
Figure 1.2: ATQ mechanism of action. [26] 
 
It is well established that ATQ has a long half life (70 to 84 hours), exert its effects on the 
parasite within minutes after drug treatment [27], can be administered via the oral rout and   
has an excellent safety profile and tolerability. The most common registered side effects 
are rash, fever, vomiting, diarrhea, abdominal pain and headache [28], and there is no 
registration of any side effects that obligate withdrawal of therapy[21]. The absence of 
severe side effects of this drug can be attributed to its selectivity as mentioned above.  
Despite of these advantages; ATQ is associated with some limitations that affect its 
effectiveness.  
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Different approaches are employed to prolong the pharmacological activity, increase oral 
bioavailability and decrease inter-individual variability of ATQ.  In general, the prodrug 
approach is one of polices that is used to enhance the pharmacokinetic behavior of drugs 
like ATQ.  It includes the conjugation of the parent drug to a linker to produce a system 
that is able to release the parent drug once in the body. The next section shed the light on 
prodrugs as a powerful means in the drug development process.  
 
1.1.2 Prodrugs 
 
In the past few decades the pharmaceutical sciences have been subjected to considerable 
alterations [29] in terms of improving drug drawbacks related to pharmacokinetic 
(absorption, distribution, excretion, and metabolism) pharmaceutical and biological 
performance of existing drugs which may hinder drug development course [30].  
Overcoming the undesirable physicochemical, biological and organoleptic properties of 
some existing drugs [29] can be achieved through the development of new chemical 
entities with desirable efficacy and safety. However, this is an expensive and time 
consuming process that needs a screening of thousands of molecules for biological activity  
[31] in addition to the rigorous rules and criteria that are applied today for developing new 
drugs [16]. So that,  it becomes much more feasible to modify and improve the properties 
of already existing drugs through exploring the prodrug approach [31] in order to get red of 
their undesirable features and to increase their commercial  life cycle and patentability 
[30].  
Prodrugs are inactive forms of active drugs that are designed to exhibit pharmacological 
activity after an enzymatic or chemical reaction when they have been administered into the 
body [32]. Prodrug approach is a promising and well established strategy for the 
development of new entities that possess superior efficacy, selectivity and reduced toxicity 
over their parent compounds. Hence an optimized therapeutic outcome can be 
accomplished[31]. 
Approximately, 10% of all worldwide marketed medicines can be categorized as prodrugs, 
and in 2008 alone, 33% of all approved small-molecular-weight drugs were prodrugs [33], 
and this confirms the success of prodrug approach [30]. 
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In general, prodrugs are designed to 1) improve aqueous solubility ,2) to enhance 
permeability through modifying lipophilicity, 3) to achieve site specific delivery and  to 
increase GI absorption  through targeting specific transporters and enzymes 4) to improve 
taste, odor and other pharmaceutical and pharmacokinetic properties[31]. 
The classic prodrug approach is focusing on changing physicochemical parameters. 
Recently, modern computational methods are used to design linkers for drugs, more details 
are provided in the following section. 
1.1.2.1  Design of innovative prodrugs using modern computational methods 
 
In a similar manner to that utilized for drug discovery, modern computational methods 
based on molecular orbital and molecular mechanics methods are explored for the design 
of innovative prodrugs for drugs containing hydroxyl, phenol, or amine groups. For 
example, mechanisms for several enzyme models that have been utilized to understand 
enzyme catalysis have been recently studied by Karaman’s group and used for the design 
of some novel prodrug linkers [34]. The classic prodrug approach was focused on altering 
various physiochemical parameters, whereas the modern computational approach, 
considers using a design of linkers for 
drugs having poor bioavailability, to provide the parent drugs in a controlled release 
manner, and thus improving their bioavailability. In addition, since the linkers used are 
relatively small molecules, it is expected that the prodrugs themselves might be with 
considerable biological effects before they interconvert to the parent drugs.  
 
Using modern computational methods like DFT, molecular mechanics and ab initio 
methods, numerous enzyme models were explored for determining the factors playing 
dominant role in governing the reaction rate in such models. Among the enzyme models 
that  have been studied are: (a) proton transfer between two oxygens and proton transfer 
between nitrogen and oxygen in Kirby’s acetals [35] (b) intramolecular acid-catalyzed 
hydrolysis in maleamic acid amide derivatives [35] (c) proton transfer between two 
oxygens in rigid systems as investigated by Menger [36]; (d) acid-catalyzed lactonization 
of hydroxyl-acids as studied by Cohen [37] and Menger; and (e) SN2-based cyclization as 
studied by Brown [38],  Bruice [39], and Mandolini  [40]. 
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The interconversion of a prodrug to the parent drug at the target site is a necessity for the 
prodrug approach to be successful [41]. The major obstacle facing the prodrug approach is 
the difficulty in predicting the bioconversion rates, and thus the pharmacological or 
toxicological effects of the prodrugs [42] [43]. 
Karaman’s studies on intramolecularity [43] have revealed that there is a necessity to 
further explore the reaction mechanism for determining the factors affecting the reaction 
rate. Unraveling the reaction mechanism would allow for better design of an efficient 
chemical device to be used as a prodrug linker that can be linked to a drug moiety which 
can chemically, and not enzymatically, cleaved to liberate the active drug in a 
programmable and controlled manner. 
For ATQ, Bruice’s model was employed to help in the design of ATQ prodrugs that have 
the expected characteristics.  
 Bruice’s systems 1–5 scheme 1.1 indicate that the rate enhancement in the cyclization of 
di-carboxylic semi-esters 1–5 is solely the result of strain effects and not as a result of 
proximity orientation due to the ‘reactive rotamer effect, scheme 1.2. 
 
 
 
 
Scheme 1.1: Chemical structures for di-carboxylic semi-esters 1-5. 
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R= p-bromophenyl or ATQ moiety. 
Scheme 1.2: Schematic representation of the reactants in the cyclization reactions of 
dicarboxylic semi-esters 1-5 and ATQ ProD 1-ProD 5. rGM is the distance between the 
nucleophile (O1) and the electrophile (C6). 
 
In addition, it was found that the activation energy in systems 1-5 is dependent on the 
difference in the strain energies of the tetrahedral intermediates and the reactants, and there 
is no correlation between the cyclization rate and the distance between the nucleophile and 
the electrophile (rGM). Therefore, the inter-conversion rates of atovaquone prodrugs to 
atovaquone can be programmed according to the nature of the prodrug linker [44].  
                                   
1.2 Problem statement 
 
Given the severity of Malaria, continual development of drug resistance and the 
undesirable safety profile of some existing medications, efforts were directed toward 
development of more effective, better tolerated medications with lower propensity to 
develop resistance, intended for the treatment of this endemic disease [8].
  
ATQ hold promise in malaria treatment, owing to its unique mechanism of action, 
effectiveness and safety. However, ATQ has poor oral bioavailability (<10% under fasted 
condition) and variable oral absorption , and this is due to its poor  aqueous solubility (<0.2 
μg/mL) that results from its lipophilic structure Log P= 5) [45]. Consequently, this results 
in low and variable plasma and intracellular levels of the drug which is an important 
determinant of therapeutic outcome [46]. It was demonstrated that low drug plasma  
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concentrations is a powerful  means for the promotion of resistant parasites [47] eased 
morbidity and mortality among children [48]. Furthermore, ATQ is an expensive 
medication [49]. ATQ oral bioavailability can be increased either by fatty food intake [50], 
or administering larger amount of the drug to recompense for low oral absorption and to 
reach therapeutic plasma concentrations [20]. This practice is considered to be costly with 
expensive drugs like ATQ. Altogether, these procedures hinder the use of ATQ in poor 
developing countries in the time in which ATQ is considered to be the standard 
antimalarial [28]. 
Thus, the adoption of strategies to protect ATQ against resistance is an urgent need [16]. 
Accordingly, to achieve therapeutic success, ATQ solubility improvement strategies 
should be addressed; in order to meet the medical needs in malaria treatment. 
 
 
1.3 Goals and Objectives 
1.3.1 Research goals 
 
In the view of this background and continuing Karaman’s study on design and synthesis of 
ATQ prodrugs, this research was conducted to synthesize a previously designed ATQ 
prodrug, through linking ATQ to a di-carboxylic semi-ester linker, like succinic anhydride 
(Bruice’s enzyme model), to produce a system that is more hydrophilic than its parental 
drug, and is able to release ATQ in a chemically driven controlled manner, once in the 
body. 
Consequently, novel ATQ prodrug that serve in providing an alternative treatment option 
to the medical community that may help in addressing the critical need in malaria 
treatment will be introduced. 
 In accordance to the thesis in hands, ATQ prodrugs are expected to fulfill the following 
requirements: (1) enhanced water solubility; (2) improved oral bioavailability; (3) 
controlled release rate; (4) predicted plasma levels and (5) improved antiparasitic activity. 
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1.3.2 Specific Objectives 
 
In this context, to achieve our research goal the following specific objectives have to be 
accomplished: 
1- To extract ATQ from (Mepron®) GlaxoSmithKline, tablets (250 mg Atovaquone + 
100 mg Proguanil Hydrochloride).  
2-  To synthesize ATQ succinate, by conjugating ATQ with succinic anhydride, 
through, simple one step chemical reaction. 
3- To purify and characterize the proposed prodrug using several purification and 
characterization techniques. 
4-  To perform in vitro prodrug kinetic analysis in different pH solutions (pH 2.2, pH 
5.2 and pH 7.4). 
 
1.4. Research Questions 
 
The research questions for the thesis in hand are: 
1. Would it be possible to link ATQ to water soluble linker via chemical synthesis? 
2. Will the prodrug have superior water solubility over ATQ? 
3. Will the prodrug be able to release ATQ in a controlled manner? 
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Chapter Two 
Literature Review 
 
Accumulating evidence suggests that ATQ low solubility and hence low oral 
bioavailability and variable plasma concentration limits ATQ inherent efficacy,[45], [3]  
[51]  ,[52]. 
In addition, several studies reported that sufficiently high ATQ plasma levels should be 
achieved  to obtain the desired therapeutic response [45]. It was demonstrated in clinical 
study with a conventional tablet formulation, that the therapeutic response of ATQ against 
Pneumocystis carinii Pneumonia is reliant on plasma steady-state levels of the drug [20]. 
Moreover, Chung, Ferreira et al [53] mentioned that resistance to ATQ was reported which 
is believed to be a result of low and variable plasma levels that results from variable oral 
absorption. This conclusion could be supported by the fact that inconsistent drug plasma 
levels will provide the parasite with the opportunity to form resistance against drugs. All of 
the mentioned complications result from ATQ lipohilic properties. 
Despite of this, there is a general agreement that this problem is solvable [45], [3], [51], 
[52]. So, different techniques were adopted in order to minimize solubility and 
bioavailability problems of ATQ. 
2.1 Approaches adopted to enhance ATQ aqueous solubility 
 
Atovaquone was firstly commercialized as tablets (Mepron®), from which complete oral 
bioavailability can’t be achieved. About 21% absolute bioavailability of Mepron® tablets 
was obtained in HIV seropositive volunteers in the fed state [54]. Therefore, Different 
groups focused on improving ATQ solubility via several approaches, for example: 
Comley, Yeates et al [45], Karaman and Hallak [3], Hughes, Dorenbaum et al [51], , 
Dixon, Pozniak et al. [52], etc… 
Most work is directed toward improving ATQ formulation to enhance bioavailability. 
Strategies that are employed focus on an increment of the specific surface area of 
atovaquone particles and/or its solubility in adequate solvents or micelles to facilitate its 
dispersion in aqueous media. 
 For example, Cotton, 1995 [55]  developed micronized ATQ suspension and compared it 
with ATQ tablets, and he found that micronized ATQ suspension achieved 2 fold increase 
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in drug bioavailability compared to that with tablet formulation of the same dose. These 
findings were reported in both the fed and fasted state [52]. It was indicated earlier that 
ATQ absorption can be increased when administered with food [52] for both tablet and 
suspension formulations. It was stated that a1.4-fold increase in ATQ absorption was 
obtained in the fed state, compared to that achieved in the fasting state [50]; and this 
amount can be higher depending on the fat content of the meal [54]. 
Additional methods to improve atovaquone oral bioavailability have been exploited, 
including the development of nanosuspensions [56], self micro-emulsifying drug delivery 
systems (SMEDDS) [57][64], liposomes [58] or polymer nanocapsules [59]. 
In this context, Dearn and coworkers revealed in male volunteers that the administration of 
microfluidized suspensions of 0.1-2 μm average leads to 2.6-fold increase in oral relative 
bioavailability than when a  typical suspensions (of about 3 μm) was used[56]. 
 In another interesting study, Sek and collaborators examined the influence of a number of 
surfactants; selfmicroemulsifying drug delivery systems on the oral bioavailability of lipid 
based formulations of atovaquone [57]. 
 No differences were observed in beagle dogs when comparing two different (SMEDDS) 
On the contrary, the relative oral bioavailability in dogs of atovaquone was about 3-fold 
higher when incorporated in these self micro-emulsifying drug delivery systems 
(SMEDDS) than when formulated as aqueous suspension. 
Another fascinating option is the association of this drug with bio adhesive nanoparticles. 
In this case the strategy combines an increase of the specific surface area of the drug 
delivery system with the ability of these nanoparticles to develop adhesive interactions 
within the gut mucosa, which may assist in the formation of a concentration gradient 
between the dosage form and the gut mucosa, thus enhancing absorption potential.[60]. 
Despite of being attractive options, the mentioned strategies add other steps to the process, 
in addition to the increased cost. Another option is to modify the structure of the drug in 
such a way to enhance poor bioavailability by increasing aqueous solubility of the drug 
[20].  
Hage et al [61], reveals the synthesis and antimalarial activity of new atovaquone 
derivatives, which was substituted at the 3-hydroxy group by ester and ether functions. The 
compounds were assessed in vitro for their activity against the growth of Plasmodium 
falciparum,. It was demonstrated that all the compounds exhibited potent activity, with 
IC50 values in the range of 1.25-50nM, comparable to those of atovaquone and much 
higher than chloroquine or quinine [20].  
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On the other hand, Comley [45] and Karaman [3] also shed the light on modifying ATQ at 
the structural level. However, their idea was to link ATQ to a water soluble moiety to 
develop prodrugs rather than developing ATQ derivatives to enhance aqueous solubility. 
Comley developed the carbamate prodrug of ATQ 17C91 and compared plasma levels of 
17C91 with the micronized ATQ suspension in a severe combined immunodeficient mouse 
model of Pneumocystis carinii pneumonia (PCP). Comley found that there is a 3 fold 
increase in plasma levels compared to that with micronized ATQ suspension, which 
indicates that ATQ prodrugs are superior over both tablets and micronized suspensions. 
Comley prodrug 17C91 system has proved its efficacy and this confirms our expectations 
for improvement ATQ characteristics using the linker approach. However, 17C91 releases 
ATQ very rapidly (t 1/2 3 minutes at pH 7.4), in pH dependent manner without any control 
on drug releasing rate [45] .   
Another group adopted the development of ATQ prodrugs [20], in order to improve ATQ 
aqueous solubility.  The new compound is synthesized by condensation of atovaquone with 
5-methyl-4-chloromethyl dioxalone (III) in a suitable solvent system and optionally 
followed by distillation and re-crystallization to obtain Atovaquone prodrug compound of 
formula   3-(5-methyl-2-oxo-l, 3-dioxol-4-yl) methyloxy-2- trans- [(4-chloro phenyl) 
cyclohexyl][l ,4] naphthoquinone [20]. 
The main advantage of Karaman’s proposed prodrugs lies in their ability to release ATQ 
via chemical cleavage in a controlled manner depending on the nature of the linker. This 
ensures a sufficient ATQ plasma levels that can be maintained long enough due to 
controlled ATQ releasing rate, which subsequently increases the probability of therapeutic 
success [3]. 
It is worth noting that enzymes have a significant role in prodrugs transformation into the 
parent compounds. Many of the marketed prodrugs realize on this hydrolytic mechanism to 
elaborate the parent drug, by catalysis of peptidases, phosphatases, carboxylesterases or 
esterases [40]. However, this pathway is associated with obstacles that hinder its 
usefulness.  For instance, the incomplete absorption obtained with several hydrolyze-
enzymes-activated prodrugs of antibiotics, and angiotensin-converting enzyme inhibitors, 
such as enalaprilate, leads to about 50% bioavailability, because of their premature 
hydrolysis by esterases during the absorption process[40]. Additional important issue is the 
bioactivation of the prodrug by cytochrome P450 enzymes. The latter are a class of 
enzymes that accounts for about 75% of all enzymatic metabolisms of drugs, including 
several prodrugs. There is increasing evidence that genetic polymorphisms of prodrug-
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activating cytochrome P450 enzymes significantly contribute to the variability in prodrug 
activation and thus to efficacy and safety of drugs utilizing this pathway [62]. 
The prodrugs chemical approach involving enzyme catalysis is perhaps the most 
vulnerable and unpredicted approach, because there are many intrinsic and extrinsic factors 
that can affect the bioconversion mechanisms. For example, the activity of many prodrug 
activating enzymes may be flocculated due to genetic polymorphisms, age-related 
physiological changes or drug interactions, leading to adverse pharmacokinetic, 
pharmacodynamic and clinical effects. In addition, there are wide interspecies variations in 
both the expression and function of most of the enzyme systems activating prodrugs which 
could lead to serious challenges in the preclinical optimization phase[40].  
Herein, lies the significance of the of Karaman’s prodrugs, that are converted chemically 
into the parent drug, and so the challenges associated with the enzymatic hydrolysis are 
avoided like the problems of high and slow metabolizers and the consequences of these 
effects on drug effectiveness and toxicity, respectively. Likewise, the programmed release 
allows for sufficient ATQ levels that are maintained long enough in the plasma, in a 
consequence a once daily dose is allowed which leads to improved patient compliance.  
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Chapter Three 
Materials and Methods 
 
This chapter consists of two major parts. The first one is the Synthetic chemistry part 
which concerns with the reactions, reagents, solvents and materials used. And the second is 
the Kinetic studies part which describes the specific preparations and analysis used to 
investigate ATQ prodrugs hydrolysis in different pH solutions using the HPLC instrument. 
3.1 Part one 
3.1. 1 Chemicals and Instrumentation.  
3.1.1.1     Reagents 
 
 Succinic anhydride, sodium hydride (NaH), thin layer chromatography (TLC), silica gel, 
NaCl, NaOH, anhydrous magnesium sulfate MgSO4, are all purchased from Sigma 
Aldrich. Atovaquone was obtained from commercial Malarone tablets (250 mg ATQ and 
100mg proguanil) GlaxoSmithKline Inc. 
3.1.1.2     Solvents  
 
Dioxane, acetonitrile (ACN), hexane, ethyl acetate, dimethylformamide (DMF), 
chloroform (CHCl3), dimethyl sulfoxide (DMSO), NaOH, methanol (MeOH), and diethyl 
ether, tetrahydrofurane (THF) and distilled water were used directly from the bottles, and 
all were purchased from Sigma Aldrich.  
 
3.1.1.3 Instrumentation and substance identification. 
 
Chemical hazards fuming hood, vacuum pumps, hotplates, available at Karaman’s Lab in the Faculty 
of Pharmacy, Al-Quds University. FTIR, pH meter, HPLC and rotary evaporator are available at Al-
Quds University. 
1
H-NMR and LC/MS were taken at the Hebrew University (the names of the 
companies are provided below).  
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All of these instruments were employed to characterize, and to describe the physicochemical 
properties of our compound of interest. 
 
3.1.1.3.1 Melting point determination by capillary method. 
 
Capillary method is commonly used in chemistry labs to determine the melting points of 
solid substances. This technique is easy and requires a small amount of the material. It is 
performed by introducing a small amount of the solid into a one end sealed capillary tube, 
which is then fixed into a thermometer, then dipped into an oil bath. Heating of the oil bath 
should be done slowly and gently, to ensure uniform heating of the sample and the 
thermometer. Then, the temperature range over which the sample starts to melt is recorded 
to be as the melting point of the material. 
3.1.1.3.2 Log P 
 
Log P was determined using Chem draw Ultra 7 program [63]. 
 
3.1.13.3   High  performance Liquid Chromatography HPLC.  
 
 HPLC from (Waters 2695: Israel), (Shimadzu corp. Japan), and waters Micromass® Masslynx ™ 
detector with Photo diode array (PDA) (Waters 2996: Israel). Data acquisition and control were 
carried out using Empower ™ software (Waters: Israel). 
Analysis was done using C8, 4.6 mm x125 mm, 5 μm particle size, protected by XBridge® C8 guard 
column. Micro filters 0.45μm porosity were used (Acrodisc® GHP, Waters). The C-8 (1 gm) 
cartridges 6cc single use for laboratory use, were purchased form Waters Company (Milford, MA, 
USA). 
3.1.1.3.4 pH meter  
 
pH values were recorded on pH meter model HM-30G: TOA electronics ™ was used to measure  pH 
values for prepared buffers. 
3.1.1.3.5  FT-IR 
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All infrared spectra (FTIR) were obtained from KBr (potassium bromide) matrix 
 (4000–400 cm-1) using a PerkinElmer Precisely, Spectrum 100, FT-IR spectrometer.  
 
3.1.1.3.6 Nuclear magnetic resonance spectroscopy (
1
H -NMR)  
 
All NMR spectra were gained by using the 400 MHz Varian NMR spectrometer. One of 
the experimental samples was run in DMSO-d6 and the other in CDCl3. 1H NMR 
experiments are stated in parts per million (ppm) downfield of TMS. 
The following symbols used for 1H NMR peak investigation: chemical shift (δ ppm), 
multiplicity (s =singlet, d = doublet, t = triplet, q = quartet, m = multiplet), integration and 
coupling constant (Hz). All NMR data were analyzed by MestReNova Software. 
 
3.1.1.3.7 Liquid Chromatography- Mass Spectroscopy (LC-MS)  
 
HPLC–MS/MS Shimadzu prominence high performance liquid chromatography system 
(Shimadzu corp. Japan) was employed to record LC/MS measurements, at the Hebrew 
University. 
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3.1.2 Chemical synthesis and purification 
 
This section describes the chemical reactions of linking ATQ to succinic anhydride to yield 
ATQ succinate prodrug.   
3.1.2.1  ATQ extraction from Malarone tablets 
 
ATQ was isolated as follows. Twelve Malarone tablets (3000 mg, 8.19 mmol) were 
crushed using a mortar and pestle. The resulting powder that consists of ATQ, proguanil 
and other ingredients was washed with 9 ml chloroform (CHCl3) added on 3 portions in 
order to dissolve ATQ while other ingredients are insoluble, then filtration was done and 
the container was washed with CHCl3 to remove any residual powder. ATQ was further 
extracted using CHCl3 and a saturated  NaCl solution (NaCl was added to exert salting out 
effect).The organic layer was separated and the aqueous layer was further extracted with 
CHCl3, then the combined organic layers were dried over anhydrous MgSO4  to make sure 
the complete removal of H2O, then CHCl3 was evaporated. Then yellow ATQ powder was 
collected and further purified by recrystallization using ACN (sufficient quantity). After 
recrystallization filtration was done to obtain precipitated ATQ, then the precipitate was 
dried and collected. Thus dry and pure ATQ was ready to be used. Afterwards, the product 
was tested by melting point (M.P), FT-IR, 
1
HNMR and LC/MS.                 
3.1.2.2 ATQ Succinic anhydride conjugation reaction 
 
This was prepared as follows.  An oven dried round bottom flask was charged with 30mL 
THF, then 500 mg (1.363 mmol) of ATQ was added to the pot followed by adding 3 
equivalents of  NaH (4.089 mmol). The addition of NaH was performed at 10 ᵒc that was 
accomplished by placing the RBF on an ice bath and the temperature of the bath was 
controlled with the aid of a thermometer. A magnetic stirrer was placed in the RBF. After 
15 minutes, a 136 mg (1.363 mmol) of succinic anhydride was added to the reaction pot at 
10ᵒc. The flask was air-tightened and closed with a flexible rubber stopper. The reaction 
was left over night at room temp for 3 days and monitored by TLC to ensure reaction 
completion using ethyl acetate and hexane (1:5) system as an eluent. 
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3.1.2.3 Purification of ATQ succinate prodrug using column chromatography 
 
ATQ succinate prodrug was purified as follows. 
The mixture was purified using conventional column chromatography. The column was 
prepared conventionally using silica gel that was purchased from Sigma Aldrich; the 
starting eluent is 10% ethyl acetate and 90% hexane. The polarity of the eluent was 
increased gradually until the compound is eluted out using 15% ethyl acetate and 85% 
hexane. TLC was performed continually as the fractions were obtained, to ensure product 
elution. 
The fractions were collected and the solvent was evaporated by the rotary evaporator, then 
the resulting pale yellow prodrug was dried to yield 30% product. Then a full 
characterization of the prodrug was done by melting point, FT-IR, 1HNMR and LC/MS.  
3.2 Part Two 
3.2.1 Kinetic studies on the stability of ATQ succinate prodrug at 
different buffer conditions 
3.2.1.1 In vitro conversion time evaluation 
 
In vitro conversion time into the parent drug in aqueous media was evaluated.This was 
accomplished by evaluating chemical hydrolysis of the prodrug at pH 2.2, pH 5.5 and pH 
7.4 solutions. 
In order to determine the hydrolytic rate of the prodrug at different pH conditions; a 
specific preparations were performed as follows. 
a) Buffer preparation: 7 gr. KH2PO4 was dissolved in 1L water, this yielded a 
solution that has a pH of 4.2 then pH was adjusted by either NaOH or 1N HCl to 
get the desired pH buffer. 
b) Stock solutions: 1000 ppm stock solution of each ATQ and ATQ succinate   
prodrug was prepared by dissolving 25mg ATQ and ATQ prodrug in 25 ml DMF 
using a volumetric flask. 
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c) Dilution: A 500 ppm of ATQ and ATQ prodrug solutions were prepared by 
transferring 5ml of 1000 ppm stock solutions  of each ATQ and ATQ prodrug 
prepared in (b)  to a 10 ml volumetric flask and diluting it  using DMF and the 
corresponding buffer. 
Note: Because both ATQ and ATQ succinate prodrug have poor solubility in the 
three buffers, dilution was made by adding 5ml DMF and the volume was 
completed with each corresponding buffer to get clear solutions. 
3.2.1.2 HPLC analysis 
 
Injections into HPLC apparatus was made at (zero time,1,2 ,3,4,5 ,24 hrs after sample  
preparation then after one weak and so on, till 50% prodrug degradation was took 
place. 
3.2.1.2.1 Chromatographic conditions 
 
It is significant to mention that different attempts were made to optimize the mobile phase 
composition, pH, detection wave length, and the column used for the separation process. 
Our trials continued until the best possible chromatograms were obtained. The conditions 
that are tried are shown in the tables below. 
As indicated in table (3.2), acetic acid was used to achieve acidic medium, (low pH of the 
m.ph) as an attempt to maintain the drug and the prodrug in unionized form. It is known 
that a buffered mobile phase is used for ionized compounds in order to maintain them in a 
specific form, so a reliable retention time is obtained in all runs. However, chromatograms 
show that ATQ prodrug is degraded when this mobile phase composition was used.  Thus, 
the conditions were re-modified and the use of acetic acid was omitted, tables (3.3) and 
(3.4). This leads to the appearance of ATQ prodrug peak without any degradation. 
However, the retention time of ATQ is relatively high (20 minutes) when these conditions 
were used. So, the elution was re-modified to an isocratic one using ACN: H2O( 90:10), in 
addition,  C8  column  was used instead of C18 column (ATQ and ATQ  prodrug stuck to 
the column due to their lipophlic structure)  which allows both of the drug and the prodrug 
to elute earlier (less than 5 minutes) with a good separations , tables (3.5) and (3.6). 
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The appropriate wave length λ was found to be 280 nm in all conditions. 280nm was 
chosen instead of 303nm, because at 280nm both the drug and the prodrug show the finest 
absorbance, while when 303 nm was used the prodrug peak was undetected.  
Then the disappearance of the prodrug with time was followed up. Concentration versus 
time was plotted and hydrolysis rate at different buffers was estimated.  
Table 3.1:  The initial HPLC conditions that are used. 
Condition I Stationary 
phase 
Mobile phase Flow 
Rate 
Run 
Time 
λ Injection 
volume 
 C18, 125 mm Gradient 
elution 1 
1ml/min 20 mins 303 nm 10µl 
 
Table 3.2: Gradient elution 1, in which B is ACN and C is 0.5%CH3CO2H in water. 
 
Number 
Time 
(min) 
Flow 
(ml/min) 
% B %C 
1  1 30 70 
       2 3 1 30 70 
3 8 1 90 10 
4 12 1 90 10 
5 13 1 30 70 
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 Table 3.3: the modified chromatographic conditions. 
Condition 2 Stationary 
phase 
Mobile phase Flow 
Rate 
Run 
Time 
λ Injection 
volume 
 C18, 125 mm Gradient 
elution 2 
1ml/min 20 mins 303 nm 10µl 
                   
 
Table 3.4:  Gradient elution 2, in which B is ACN, C is water. 
Number 
Time 
(min) 
Flow 
(ml/min) 
% B %C 
1  1 30 70 
2 3 1 30 70 
3 8 1 90 10 
4 12 1 90 10 
5 13 1 30 70 
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Table 3.5: The optimized HPLC conditions. 
Condition 3 Stationary 
phase 
Mobile phase Flow 
Rate 
Run 
Time 
λ Injection 
volume 
 C8,5µm4.6x125n
m  
Isocratic flow 
90:10 ACN: H2O 
 
1.5ml/
min 
5 mins 280nm 10µl 
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Chapter 4 
Results and discussion 
 
ATQ Succinate prodrug (ProD1) is successfully obtained, and all the gained data are 
consistent with the proposed compound. A full description and analysis of the results are 
provided below. 
4.1 Chemical synthesis 
 
After ATQ extraction, a complete characterization of the obtained yellow powder was 
done by melting point, FT-IR, and H-NMR. M.p= 224ᵒC. 3397 phenol vibration, 3086 
aromatic C-H vibration, 1647-1659 c=o stretching vibration, 727 aromatic chloride. H1-
NMR (DMSO-d6, 400 MHz):δ 8.13(d,1H), 8.07(d, 1H), 7.76(t, 1H), 7.68 (t, 1H), 7.48 (s, 
1H), 7.28 (d, 2H), 7.18 (d, 2H), 3.16 (t, 1H), 2.63 (t, 1H), 2.2 (m, 2H), 1.96 (d, 2H), 1.75 
(d, 2H), 1.58 (q, 2H).   
The scheme shown below describes the chemical reaction of ATQ and succinic anhydride 
(linker) to yield 30% of our proposed ATQ prodrug. M.p ῀280ᵒC. , IR (KBr/νmax cm
–1
)  , 
3379 OH STRECH, 1750 aliphatic C=O stretch, 1647-1659 c=o stretching vibration, 727 
aromatic chloride  , 1HNMR (400Hz, DMSO-d6) δ 7.99(dd,2H), 7.84(dt,1H),7.77(dt,1H), 
7.33(s,4H),3.31(s,3H),3.07 (t,1H), 2.56(t, 1H), 2.22(q,2H),2.12(d, 2H),1.65(d,2H), 1.56 
(q,2H), 1.49 (s, 1H), m/z 467 (M+1). 
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Scheme 4.1: shows the conjugation reaction of ATQ and succinic anhydride. Conditions 
and reagents :( i): THF, (ii): NaH, (iii): 10 ᵒc then R.T, (iv): 3 days. 
The scheme demonstrates a conjugation reaction in which a nucleophilic attack (SN2 
reaction) takes place between the OH group of ATQ and the electrophile center of succinic 
anhydride. This attack results in ring opening of succinic anhydride and the formation of 
an ester bond in the given prodrug, which is supposed to be cleaved once in the body 
depending on the pH of the medium.  
To ensure the progress of the reaction in the suggested mechanism, specific reagents were 
used at certain conditions. For example, THF is a commonly used basic solvent in 
chemical reactions; it has a dielectric constant of 7.58. The basic conditions created by the 
solvent may encourage the deprotonation of the hydroxyl group of ATQ, hence increasing 
its nucleophlicity. 
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Moreover, Sodium hydride is a frequently used base to deprotonate alcohols, phenols, 
amides, ketones, esters and other functional groups for the promotion of their nucleophilic 
substitution. [64].The reaction was carried out at 10 c, because the enolate intermediate 
that forms after NaH addition is stable at low temperature rather than high Celsius degrees, 
Scheme (4.2). 
O
O
OH
Cl
NaH
O
O
O-
Cl
Enolate intermediate
 
Scheme 4.2: demonstrates the formation of enolate intermediate after adding NaH to ATQ. 
The intermediate shown in the figure is given the time to be formed after  mixing ATQ 
with NaH, and this is the reason of adding succinic anhydride after 15 minutes to the 
reaction pot. 
TLC was conducted to monitor reaction progress using an eluent system that is composed 
of ethyl acetate and`` hexane in a ratio of 1:5. This ratio was specifically employed after 
various attempts to choose the best solvent system. For example 1:5, 2:5 methanol: hexane 
and 2:5 ethyl acetate: hexane were tried until the best R.f values was obtained for the 1:5 
ethyl acetate: hexane. 
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After the reaction was completed, a purification of the prodrug was done using column 
chromatography. Then a purity and identity confirmation assessments were conducted. A 
demonstration of the results of these examinations is provided in the following sections. 
4.1.1 ATQ succinate prodrug identification 
4.1.1.1 Log P 
 
Log P is an important physical property that demonstrates the extent of aqueous solubility 
of certain compound. Log P can be measured by estimating the ratio of the concentration 
of the compound in an organic solvent (usually 1-octanol) to the concentration in aqueous 
solvent (water). High ratio means high organic solubility and vice versa [65]. Log P of 
ATQ ProD1was estimated using ChemDraw Ultra 7, to be 3.57, while that of ATQ is 5.1 
[66]. 
4.1.1.2 Melting point of ATQ succinate prodrug 
 
As a preliminary analysis of the material that was obtained from the reaction and purified 
by column chromatography, melting point was performed for both ATQ and the proposed 
prodrug by capillary method as a technique that is commonly employed in chemistry labs 
to analyze solid chemical materials and provides an initial information about the identity 
and the purity of different compounds. 
It was given that the melting point of ATQ was 224ᵒC, while that for ATQ prodrug was 
280 ᵒC which is different from that of ATQ. This gives a preliminary indication that the 
compound is not ATQ. 
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4.1.1.3  FT-IR  
4.1.1.3.1 FT-IR Spectra of ATQ: 
Operator 174
Name
Sample 174 By Operator date Monday, March 19 2012
Description
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Figure 4.1: FT-IR spectrum of ATQ. 
The spectrum analysis is as follows: 
3397 phenol vibration, 3086 aromatic C-H vibration, 1647-1659 c=o stretching vibration, 
727 aromatic chloride. 
4.1.1.3.2 FT-IR Spectrum of ATQ ProD1: 
Operator 1069_1
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Sample 1069 By Operator date Wednesday, April 17 2013
Description
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Figure 4.2: FT-IR Spectrum of ATQProD1. 
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3379 OH stretch, 1750 aliphatic C=O stretch, 1647-1659 c=o stretching vibration, 727 
aromatic chloride. 
It can be concluded from the spectrum of the prodrug that an aliphatic stretching of C=O 
group at 1750 is present, which is most likely indicate the presence of the carbonyl group 
of the succinate linker, in addition to the presence of signals of common groups in both the 
drug and the prodrug. 
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Figure 4.3: Chemical structure of ATQ. 
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Figure 4.4: 
1
H-NMR of ATQ; whole spectrum. 
 
 
Figure 4.5: 
1
H-NMR of ATQ; aliphatic part. 
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Table 4.1: Assignment of H-NMR signals of the aliphatic part of ATQ. 
 C and C’ D and D’ E F Total # of 
Hs 
Chemical 
shift 
1.51 
C’ 1.62 
2.2 
D’ 1.88 
2.6 3.1  
Integration 
1H           
1.03 
C :  
2.14/1.03=2.07 
 2 Hs 
C’: 
2.02/1.03=1.96 
 2 Hs 
D: 
2.02/1.03=1.96 
 2 Hs 
D’ : 
2.02/1.03=1.96 
 2 Hs 
1.06/1.03= 
1.02 
   1H 
1.18/1.03= 
1.1 
   1H 
 
 
10 Hs 
Splitting Q 
Or dt 
Q 
Or dt 
P p  
 
 
Figure 4.6: 
1
H-NMR of ATQ; aromatic part. 
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Table 4.2: Assignment of H-NMR signals of the aromatic part of ATQ. 
 A B H I Total Hs 
Chemical shift 7.33 7.33 7.99 7.8  
Integration 
(Ʃ areas=19.6) 
19.6 19H 
 ??    1H 
1H=1.03 
4/1.03= 
3.9     4 Hs 
For A and 
B  
Included 
in  A 
peak 
2/1.03= 
1.9   2 Hs 
1.97/1.03= 
1.9    2 Hs 
  
8Hs 
Splitting  d d d d  
 
 
4.1.1.4.2 H-NMR of ATQ succinate prodrug 
 
Figure 4.7: Chemical structure of ATQ succinate prodrug (ATQ ProD1). 
The H-NMR spectrum of ATQ succinate prodrug is shown the figure below. 
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Figure 4.8: ATQ ProD1 
1
 HNMR spectrum. 
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Figure 4.9:
1
 H-NMR of ATQ ProD1; the aliphatic part. 
 
Figure 4.10:
1
 H-NMR of ATQ ProD1; the aromatic part. 
 
1HNMR (400Hz, DMSO-d6) δ 7.99(dd,2H), 7.84(dt,1H),7.77(dtt,1H), 
7.33(s,4H),3.31(s,3H),3.07 (t,1H), 2.56(t, 1H), 2.22(q,2H),2.12(d, 2H),1.65(d,2H), 1.56 
(q,2H), 1.49 (s, 1H). 
39 
 
As illustrated in the spectrum of ATQ Succinate, the pattern of signals is almost consistent 
with the structure of the proposed compound.  The signals that appear at the aromatic 
region indicate the aromatic protons of the aromatic rings in the compound. the singlet 
signal that appear at 7.33 is integrated to 4 protons of ring E, figure (4.7), while signals that 
appear at 7.99, 7.84 and 7.77 splitted as dd, dt and dt and integrated into 2H, 1H and1 H 
each, additionally they appear at the aromatic region as mentioned earlier and therefore 
they were assigned as the protons of ring B, figure (4.7). 
The assignment of the aliphatic part of the compound is a little bit more complicated, as 
with the available data it is difficult to make an absolute assignment of these signals. 
The protons of the cyclohexane ring and their integrations are indicated with arrows as 
shown in figure (4.9) and (4, 10). The triplet signal that appears at 2.6 is assigned as being 
most likely the protons of the succinate linker of the prodrug; this almost indicates that the 
linker was successfully joined to ATQ. 
 
 
 
 
 
 
 
 
40 
 
4.1.1.5 LC/MS. 
 
 
Figure 4.11: LC/MS spectrum of ATQ ProD1. 
The figure shows the LC/MS result of ATQ succinate prodrug; molecular formula  
(positive mode) m/z 468 (M+\1), that has a M.W OF 467 g/mol. LC//MS shows that the 
proposed compound has a M.W of 468g/mol. 
  An additional confirmation of the identity of the proposed compound is HPLC assessment 
that was made as a complementary analysis in order to reveal the behavior of the drug and 
the prodrug at certain chromatographic conditions.  
The chromatograms of ATQ and ATQ prodrug are shown in the section below. 
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4.2 HPLC ANALYSIS 
 
Figure 4.12: ATQ chromatogram. 
 
Figure 4.13: ATQ succinate prodrug chromatogram. 
 
 
The chromatograms shown above are for ATQ and ATQ succinate prodrug, respectively. 
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The chromatograms ensure the presence of two different pure compounds, as the retention 
time of ATQ is 2.55 mins while for ATQ prodrug is 3.1 mins. 
Altogether, the results that are shown previously indicate that ProD1 is successfully 
synthesized and purified, and that the recorded data are consistent with the proposed 
compound. 
4.2.1 Kinetic studies on the stability of ATQ ProD1 at different buffer conditions 
 
Conversion time into the parent drug in aqueous media was evaluated .This was carried out 
by evaluating chemical hydrolysis of the prodrug at pH2.2, pH 5.2 and pH 7.4 solutions 
using HPLC. These conditions are corresponding to the pH conditions of the stomach (the 
pH of the stomach in the fasted state ranges from 1.2 to 6.4, median 1.7, and in the fed 
state it reaches 7, and then decreases gradually within 1.5 hrs) [67], pH of the small 
intestine and the pH of the blood, respectively. Injections into HPLC apparatus was made 
after sample  preparation at (zero time,1,2 ,3,4,5 ,24 hrs, then after one weak and so on, till 
50% prodrug degradation took place. 
4.2.1.1 Chemical hydrolysis (release kinetic studies) 
 
It will be clear in the following sections that at constant pH and temperature the reaction 
displayed strict first order kinetics as the kobs was fairly constant and a straight plot was 
obtained on plotting log concentration of residual prodrug vs. time. The rate constant (kobs) 
and the corresponding half-lives (t1/2) for atovaquone ProD 1 in the different media were 
calculated from the linear regression equation correlating the log concentration of the 
residual prodrug vs. time, table (4.3). 
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      Table 4.3: A summary of t1/2 of ProD 1at the listed pH values. 
pH value T1/2 Kobs 
pH 2.2 693 hrs (28.8 days) 0.001 
pH5.2 53.3 hrs (2.2 days) 0.013 
pH7.4 77 hrs (3.2 days) 0.009 
 
                            Table 4.4: Shows the major chromatographic parameters. 
Chromatographic parameters  pH 2.2 pH 5.2 pH 7.4 
Rs (resolution) 0.932 0.78 1.67 
α (selectivity) 1.39 1.84 1.82 
KATQ (capacity factor for ATQ) 1.4 1.44 1.72 
KproD1 (capacity factor for ATQ 
prodrug) 
1.97 2.66 3.1 
                                
                              Figure 4.14: Shows the calibration curve of ATQ ProD1. 
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4.2.1.1.1 ATQ ProD1 hydrolysis at pH 2.2 
 
              
 
Figure 4.15: first order hydrolysis of ATQ Succinate prodrug at pH 2.2 
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Figure 4.16: ATQ succinate prodrug chromatogram at t=9 hrs and t= 336hrs (14 days), 
respectively. 
 
 
 
4.2.1.1.2 ATQ Succinate prodrug hydrolysis at pH 5.2. 
 
      
 
Figure 4.17: shows the behavior of ATQ Succinate  at pH 5.2. 
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Figure 4.18: ATQ Succinate prodrug pH5.2, t=3 hrs and t= 40 hrs, respectively 
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4.2.1.1.3 ATQ Succinate prodrug hydrolysis at pH 7.4. 
 
            
  
Figure 4.19: first order hydrolysis ATQ Succinate hydloysis at pH 7.4. 
             
                                                             
Figure 4.20: ATQ Succinate prodrug at 7.4 after 3 hrs and t=8 days, respectively. 
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According to Bruice proposed mechanism of dicarboxylic acid semi ester hydrolysis, and 
based on the results listed in table (4.3), it can be concluded that ATQ prodrug hydrolysis 
rate is increased as the pH of the medium increased (comparing the results at pH 2.2 vs. the 
results at pH 5.5 and 7.4). This finding can be explained based on Bruice mechanism of 
intermolecular cyclyzation, which stays that as the pH of the medium is increased the ring 
closing reaction rate will increase.  
This is because at basic pH the OH group of the succinate part becomes deprotonated, 
consequently the nuceophilicity of this group will be enhanced, and this facilitates the 
nucleophilic attack of the OH group on the electrophile center, thus the ring closing 
reaction will be completed and the parent drug will be elaborated, scheme (4.1).  
To translate these findings into practice, an intravenous and oral administration of ATQ 
succinate prodrug is possible. 
The controlled release in combination with the long t1/2 of ATQ, allows for administering 
the drug once daily. This contributes in improving patient compliance and hence treatment 
outcomes. Furthermore, the controlled release of the parent constitutes a major advantage 
for highly lipophilic drugs like ATQ, since a rapid cleavage leads to drug precipitation and 
poor re-dissolution [68], figure (4.23).   
It is important to mention that succinic anhydride is particularly considered suitable linker, 
because it is produced in the body in cribs’ cycle, so it is non toxic when released in vivo 
after prodrug hydrolysis, and it becomes ionized at physiological pH, so it contributes to 
the increased solubility of the prodrug.  
Altogether, the idea of simple administration of effective drugs that treat endemic diseases 
like malaria becomes feasible and applicable.  
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                 Readily permeable once cleaved. 
                    Scheme 4.3: Shows the hydrolysis of ATQ succinate in the body. 
 
 
                                 
Figure 4.21: Shows the hydrolysis and absorption of prodrugs in the GIT. 
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Conclusions and Recommendations 
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Chapter 5 
Conclusions and recommendations 
 
5.1. Conclusions 
 
Malaria is an endemic global disease. Malaria control programs need efficacious drugs that 
can be used with ease by the populations of endemic countries. 
Several medicines are used to treat malaria; however, the limited efficacy, severe side 
effects and the appearance of parasitic resistance limit their use. 
Several lines of evidence indicate that the emergence of drug resistant parasites stimulate 
research groups to explore different approaches in an attempt to improve the characteristics 
of existing medications. 
ATQ, a naphthoquinone and ubiquinone analogue seems to be promising in the treatment 
and prevention of malaria. It is an effective drug, it inhibits electron transport in the 
parasite leading to its death, it has an excellent safety profile, and there is no registration of 
side effects that obligate stopping of therapy, it has long half life and it can be taken orally. 
Nevertheless, it has bad bioavailability and it is expensive. 
 ATQ formulation improvements is done and showed better bioavailability than 
conventional tablet dosage form. 
Prodrugs, an alternative approach lead to improved efficacy, pharmacokinetics profile and 
reduced toxicity. Additionally, prodrug approach saves money and time which is an 
important issue in drug development. ATQ prodrug 17C91 show a 3 fold increase in 
bioavailability over the improved ATQ formulation (micronized suspension) and 
conventional tablets, meaning that ATQ prodrugs are successful.  
Our research is complementary to prodrug approach, this research come out with a new 
entity that possesses superior properties over ATQ and existing ATQ prodrugs, in terms of 
efficacy, safety, physicochemical properties and drug releasing rate. Consequently, ATQ 
succiate prodrug is the desired compound that fulfills the requirements of malaria treatment 
with a standard medication like ATQ. Such effort may has implication on other studies aim 
to develop prodrugs for other antimalarial classes. 
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5.2. Recommendations and future directions 
 
To overcome or decrease drug resistance, we recommend using the right effective 
medication for the people who need it. Our future directions is to evaluate if our produced 
prodrug has any antimalarial activity, in addition to  the performance of in vivo studies of 
ATQ succinate prodrug in both animals and humans, this is most likely will be done in 
Finland. 
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 الملخص:
 
جت ثٍّ١ْٛ حبٌخ ٚفبٖ سٕٛ٠ب, ٠شىً الاؽفبي رحذ ػّش ٠ؼزجش ِشع اٌّلاس٠ب ِٓ الاِشاع اٌظح١ٗ اٌؼبٌّ١ٗ, ٚاٌزٟ رزس
سٕٛاد ٔسجٗ وج١شٖ ِٕٙب. ٚرؼضٜ ِؼظُ حبلاد اٌٛفبٖ اٌٝ اوثش اشىبي اٌّشع حذٖ ٚاٌزٟ رسججٙب ثلاصِٛد٠َٛ  5اي 
 فبٌس١جبسَ احذ اٌطف١ٍ١بد اٌّسججٗ ٌٍّلاس٠ب. 
اٌّسجت ٌٍّشع ٠طٛس ِمبِٚٗ ػذ ٘زٖ الادٚ٠ٗ ِّب ٠زٛفش ػذد ِٓ اٌؼلاخبد اٌفؼبٌٗ ٌٙزا اٌّشع اٌطف١ٍٟ, الا اْ اٌطف١ً 
٠مًٍ ِٓ فؼبٌ١زٙب ػذٖ, ِّب شىً خطٛسٖ فٟ اٌس١طشٖ ػٍٝ ٘زا اٌّشع اٌٛثبئٟ. ٚٔ١دخ ٌزٌه رُ رىث١ف اٌدٙٛد ٔحٛ 
رطٛ٠ش ادٚ٠ٗ راد ربث١ش فؼبي ػذ ِشع اٌّلاس٠ب,  ِٚٓ ػّٓ ٘زٖ اٌؼلاخبد دٚاء الارٛفبوْٛٚ , ٚاٌزٞ ٠ؼزجش ِٓ 
  ذ٠ثٗ ٔسج١ب ٚ اٌزٟ سبّ٘ذ فٟ رمذَ ػلاج اٌّلاس٠ب.الادٚ٠ٗ اٌح
ارٛفبوْٛٚ ٠زسُ ثظفبد ا٠دبث١ٗ ػذ٠ذٖ, الا اْ ثؼغ اٌّسبٜٚء اٌّزؼٍمٗ ثٗ حذد ِٓ فؼبٌ١زٗ. ِٚٓ اثشص ٘زٖ اٌسٍج١بد  
رائج١خ الارٛفبوْٛٚ اٌّحذٚدٖ فٟ سٛائً اٌدسُ ٚثبلاخض ػظبسح اٌدٙبص اٌٙؼّٟ , ٚاٌزٟ رشىً ِزطٍت سئ١سٟ حزٝ 
  ُ اِزظبص اٌذٚاء اٌٝ اٌذٚسٖ اٌذِٛ٠ٗ ٠زشاو١ض وبف١ٗ لاظٙبس فؼبٌ١خ اٌذٚاء.٠ز
% فٟ 10اٌزٟ ٠زُ اِزظبطٙب اٌٝ اٌذَ ٚ اٌدشػٗ اٌزٟ اػط١ذ ٌٍّش٠غ رشىً فمؾ اْ إٌسجٗ ث١ٓ وّ١خ الارٛفبوْٛٚ 
 حبٌخ اٌظ١بَ. ٚ٘زٖ ٔسجٗ ػئ١ٍٗ ثحبخٗ اٌٝ اٌزحس١ٓ حزٝ رزُ الاسزفبدٖ ِٓ اٌدشػٗ اٌّؼطبٖ ثبفؼً طٛسٖ ِّىٕٗ.
رزُ ص٠بدح لطج١خ اٌّشوت  ِٚٓ ٕ٘ب, رُ رحذ٠ذ ٘ذف ػٍّٕب اٌجحثٟ , ٚ٘ٛ اٌؼًّ ػٍٝ رحس١ٓ اٌّجٕٝ اٌى١ّ١بئٟ ٌٍذٚاء ثح١ث
ٚثبٌزبٌٟ ص٠بح رائج١زٗ فٟ اٌٛسؾ اٌّبئٟ. رّذ ػٍّ١خ اٌزحس١ٓ ٘زٖ ػٓ ؽش٠ك سثؾ الارٛفبوْٛٚ ة سىس١ٕه أٙ١ذسا٠ذ, 
  .دٚاء اٌٟٚ ٚاٌزٞ ٠شىً اٌدضء اٌمطجٟ, ػٓ ؽش٠ك رفبػً و١ّ١بئٟ, ٌ١زُ أزبج
ِٓ ثبلٟ ٔٛارح اٌزفبػً, ٚاػبدح ثٍٛسرٗ, ٚاسزخذاَ رمٕ١خ ػٍّ١بد اٌزٕم١ٗ ٌٍّشوت إٌبرح رشًّ, اسزخلاص ٌٍّشوت إٌبرح 
  yhpargotamorhc nmuloC اي    ٌٍحظٛي ػٍٝ ِشوت ٔمٟ.
 85
 
 رُ اٌزبوذ ِٓ ٔمبء اٌّشوت ثبسزخذاَ رمٕ١خ اي     CLPH ,RI ,RMNH.
 رُ رم١١ُ اٌؼّش إٌظفٟ ٌٍّشوت فٟ اٌّحبٌ١ً اٌزبٌ١ٗ, راد دسخبد اٌحّٛػٗ اٌّخزٍفٗ:
  ,4.7 ,5.5 ,2.2 Hp 
 ٚٚخذ اْ اٌؼّش إٌظفٟ  فٟ ٘زٖ اٌّحبٌ١ً ٟ٘ وبٌزبٌٟ:
  , ػٍٝ اٌزٛاٌٟ.ا٠بَ 8.3,ا٠بَ  8.8ا٠بَ ,2,28
ح١ث أٗ ٠زُ اؽلاق الارٛفبوْٛٚ ِٓ اٌذٚاء الاٌٟٚ ثشىً ٠ؼزّذ ػٍٝ دسخٗ حّٛػخ اٌّحٍٛي, رحذ دسخخ حشاسٖ ثبثزٗ. 
  ِّب ٠ذي ػٍٝ ٚخٛد لٜٛ ِحشوٗ ِٓ اٌشرجٗ الاٌٚٝ. وّب اْ اٌشسُ اٌجبٟٔ ٌٙزٖ إٌزبئح لذ اػطٝ خؾ ِسزم١ُ,
ٚثٙزا, رُ الاسزٕزبج اْ اٌزؼذ٠ً ػٍٝ دٚاء الارٛفبوْٛٚ لذ سبػذ فٟ ص٠بدح رائج١زٗ فٟ اٌٛسؾ اٌّبئٟ ثبٌزبٌٟ رحس١ٓ 
 اِزظبطٗ ِٓ 
فٟ رشى١ً اٌذٚاء اٌدٙبص اٌٙؼّٟ, ٚٔز١دخ ٌزٌه رحسٓ فٟ فؼٍ١زٗ فٟ ػلاج ِشع اٌّلاس٠ب اٌٛثبئٟ, اػبفخ اٌٝ اٌّسبػذٖ 
 ثبشىبي دٚائ١ٗ ِخزٍفٗ. 
  
